Abstract: This document relates to methods and materials for tissue ablation. For example, methods for using a composition including one or more ionic liquids (e.g., a composition including a LATTE solution) for tissue ablation are provided. In some cases, a composition including one or more ionic liquids (e.g., a composition including a LATTE solution) can be used to ablate tumor tissue within a mammal having cancer (e.g., to treat the mammal).

Abstract: This disclosure relates to methods and materials for embolization of one or more blood vessels (e.g., one or more arteries). For example, biomaterial compositions (e.g., BEM compositions containing PRF and one or more nanoclay materials) for embolization of one or more blood vessels (e.g., one or more arteries) within a mammal (e.g., a human) are provided.

Abstract: This disclosure relates to methods and materials for embolization of one or more blood vessels (e.g., one or more arteries). For example, hydrogel compositions for embolization of one or more blood vessels (e.g., one or more arteries) within a mammal (e.g., a human) are provided.

Abstract: A DOPA-Gelatin is disclosed in which the monophenolic group of tyrosine, a prominent amino acid in porcine gelatin, is converted into a catechol group using an enzyme-based DOPA modification technique. The resulting DOPA-Gelatin has been discovered to exhibit good mechanical strength and adhesion. Moreover, in vitro studies show that DOPA-Gelatin has no cytotoxicity with HDF and HaCaT cells, two cells typically involved in the skin wound healing process. Further RT-PCR and angiogenesis investigation showed that DOPA-Gelatin can promote the expression of wound-related genes and facilitate neovascularization. In a full-thickness dorsal defect model in mice, DOPA-Gelatin treated groups decreased the wound closure time and enhanced hair follicle growth. These results demonstrate that the DOPA-Gelatin hydrogel compositions disclosed herein are an effective functional biomaterial that can potentiate the wound healing process.

Abstract: This document provides materials and methods for permanent arterial embolization and/or enhanced vascular healing. For example, materials and methods for using bioactive tissue derived nanocomposite hydrogels to enhance vascular healing are provided.

Abstract: We have developed novel shear-thinning biomaterials using silica nanoparticles, gelatin-based polymers and polypeptides such as anti-PD-1 antibodies. Shear-thinning biomaterial technology offers enables polymers and drugs loaded inside such polymers to be easily delivered directly through catheters into target area for use, for example, in cancer therapy and immunotherapy. When a force above a certain threshold is applied to inject such materials, they “thin” and behaves as a semi-solid, allowing the material to readily flow through a catheter. When the force is removed, the material instantly becomes a soft solid with significant cohesive properties that prevent it from dislodging or breaking up.

Abstract: We have developed novel shear-thinning biomaterials using silica nanoparticles, gelatin-based polymers and small molecules such as doxorubicin. Shear-thinning biomaterial technology offers enables polymers and drugs loaded inside such polymers to be easily delivered directly through catheters into target area for use, for example, in cancer therapy and immunotherapy. When a force above a certain threshold is applied to inject such materials, they “thin” and behaves as a semi-solid, allowing the material to readily flow through a catheter. When the force is removed, the material instantly becomes a soft solid with significant cohesive properties that prevent it from dislodging or breaking up.

Abstract: This disclosure relates to methods of using shear-thinning compositions in the treatment of a vascular disorders, cancers, infections, abscesses, and fistulas.

Abstract: This disclosure relates to methods of using shear-thinning compositions in the treatment of a vascular disorders, cancers, infections, abscesses, and fistulas.

Abstract: Devices can be used to deliver pulsed electrical field for targeted cellular ablation. For example, this document describes catheter-based devices that deliver non-thermal irreversible electroporation to treat deep vein thrombosis by ablating cells of the venous thrombus to prevent cellular mechanisms that lead to clot organization, leaving the clot susceptible to physiological degradation.

Abstract: Systems and methods of using and imaging shear-thinning biomaterial compositions are provided. More particularly, systems and methods of providing reversible birth control and/or for delivering therapeutics to reproductive organs are provided. A method includes administering a biomaterial into fallopian tubes, uterus, or vas deferens of the subject, where the biomaterial is a shear-thinning nanocomposite.

Abstract: This disclosure relates to methods of using shear-thinning compositions in the treatment of a vascular disorders, cancers, infections, abscesses, and fistulas.

Abstract: This disclosure relates to methods of using shear-thinning compositions in the treatment of a vascular disorders, cancers, infections, abscesses, and fistulas.

Abstract: This disclosure relates to methods of using shear-thinning compositions in the treatment of a vascular disorders, cancers, infections, abscesses, and fistulas.